Integra LifeSciences Reports Second Quarter 2025 Financial Results

Integra LifeSciences reported financial results for the second quarter ending June 30, 2025.

Second quarter 2025 highlights include:

• Second quarter revenues exceeded guidance; adjusted earnings per diluted share (EPS) at the top end of the range.
• Second quarter revenues of $415.6 million decreased (0.6)% on a reported basis and (1.4)% on an organic basis compared to the prior year.
• Second quarter GAAP earnings per diluted share of $(6.31), compared to $(0.16) in the prior year primarily reflecting a goodwill impairment charge of $511 million, recorded during the quarter. This charge was due to the decrease in the price per share of the Company’s common stock related to a number of factors including recent tariff changes that have created broad economic uncertainty and the impact of quality, operational, and supply issues.
• Adjusted earnings per diluted share of $0.45, compared to $0.63 in the prior year.
• Full-Year revenue guidance range updated to reflect increased visibility.

“I am proud of our team’s performance and execution in the second quarter. Our strong revenue performance is a testament to our disciplined progress and the solid underlying demand trends for our portfolio of neurosurgery and tissue technology products,” said Mojdeh Poul, president and chief executive officer.

“Our transformation is underway, and I’m encouraged by the focused implementation and steady progress made against our Compliance Master Plan. Importantly, we have now completed the assessment phase at all of our manufacturing sites. Looking ahead, we are committed to advancing our remediation efforts, delivering on our commitments, and establishing the foundation of operational excellence required to position Integra for predictable and sustainable growth and profitability over the long-term.”

Click here for the full press release.